NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.266
-0.030 (-2.31%)
At close: Mar 27, 2026
NextCell Pharma AB Revenue
In the year 2025, NextCell Pharma AB had annual revenue of 9.83M SEK, down -11.13%. NextCell Pharma AB had revenue of 1.83M in the quarter ending December 31, 2025, a decrease of -41.01%.
Revenue
9.83M
Revenue Growth
+4.08%
P/S Ratio
14.34
Revenue / Employee
409.73K
Employees
24
Market Cap
141.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.83M | -1.23M | -11.13% |
| Aug 31, 2025 | 11.06M | -213.75K | -1.90% |
| Aug 31, 2024 | 11.28M | -2.68M | -19.18% |
| Aug 31, 2023 | 13.96M | 7.73M | 124.03% |
| Aug 31, 2022 | 6.23M | 1.77M | 39.82% |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 152.35M |
| IRLAB Therapeutics AB | 57.46M |
| Biovica International AB | 10.93M |
| Alligator Bioscience AB | 4.42M |
| Xintela AB | 2.28M |
| Simris Group AB (PUBL) | 1.62M |